NCT01530620View on ClinicalTrials.gov

Efficacy and Tolerability of Propiverine Hydrochloride in Patients With Neurogenic Detrusor Overactivity

PHASE3CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

June 30, 2005

Study Completion Date

July 31, 2006

Conditions
Neurogenic Urinary Bladder DisorderUrinary Bladder, NeurogenicBladder Disorder, NeurogenicUrinary Bladder Disorder, NeurogenicNeurogenic Bladder DisorderUrinary Bladder Neurogenic DysfunctionUrologic DiseasesOveractive Detrusor FunctionUrinary Incontinence
Interventions
DRUG

Propiverine hydrochloride ER (extended release)

45 mg capsule (1x1/d)

DRUG

Propiverine hydrochloride IR (immediate release)

15 mg tablet (3x1/d)

Trial Locations (3)

Unknown

Graz

Hagenow

Bucharest

All Listed Sponsors
lead

APOGEPHA Arzneimittel GmbH

INDUSTRY

NCT01530620 - Efficacy and Tolerability of Propiverine Hydrochloride in Patients With Neurogenic Detrusor Overactivity | Biotech Hunter | Biotech Hunter